- Home
- XXII vs BCLI Comparison
XXII vs BCLI Comparison
Compare XXII & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- BCLI
- Stock Information
- Founded
- XXII 1998
- BCLI 2000
- Country
- XXII United States
- BCLI United States
- Employees
- XXII N/A
- BCLI N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XXII Health Care
- BCLI Health Care
- Exchange
- XXII Nasdaq
- BCLI Nasdaq
- Market Cap
- XXII 7.0M
- BCLI 7.7M
- IPO Year
- XXII N/A
- BCLI N/A
- Fundamental
- Price
- XXII $0.74
- BCLI $1.22
- Analyst Decision
- XXII
- BCLI Strong Buy
- Analyst Count
- XXII 0
- BCLI 1
- Target Price
- XXII N/A
- BCLI $30.00
- AVG Volume (30 Days)
- XXII 288.8K
- BCLI 3.4M
- Earning Date
- XXII 05-13-2025
- BCLI 05-15-2025
- Dividend Yield
- XXII N/A
- BCLI N/A
- EPS Growth
- XXII N/A
- BCLI N/A
- EPS
- XXII N/A
- BCLI N/A
- Revenue
- XXII $23,869,000.00
- BCLI N/A
- Revenue This Year
- XXII $22.41
- BCLI N/A
- Revenue Next Year
- XXII $76.35
- BCLI N/A
- P/E Ratio
- XXII N/A
- BCLI N/A
- Revenue Growth
- XXII N/A
- BCLI N/A
- 52 Week Low
- XXII $0.70
- BCLI $0.72
- 52 Week High
- XXII $140.40
- BCLI $8.09
- Technical
- Relative Strength Index (RSI)
- XXII 32.55
- BCLI 55.90
- Support Level
- XXII $0.72
- BCLI $1.05
- Resistance Level
- XXII $0.77
- BCLI $1.18
- Average True Range (ATR)
- XXII 0.06
- BCLI 0.14
- MACD
- XXII -0.01
- BCLI 0.00
- Stochastic Oscillator
- XXII 5.25
- BCLI 23.91
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.